OBJECTIVE/ BACKGROUND: The National Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology (RUPP) Autism Network found an effect size of d = 1.2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder. This paper explores moderators and mediators of this effect. METHOD: Intention-to-treat (ITT) analyses were conducted with suspected moderators and mediators entered into the regression equations. MacArthur Foundation Network subgroup guidelines were followed in the evaluation of the results. RESULTS: Only baseline severity moderated treatment response: Higher severity showed greater improvement for risperidone but not for placebo. Weight gain mediated treatment response negatively: those who gained more weight improved less with risperidone and more with placebo. Compliance correlated with outcome for risperidone but not placebo. Higher dose correlated with worse outcome for placebo, but not risperidone. Of nonspecific predictors, parent education, family income, and low baseline prolactin positively predicted outcome; anxiety, bipolar symptoms, oppositional-defiant symptoms, stereotypy, and hyperactivity negatively predicted outcome. Risperidone moderated the effect of change in 5'-nucleotidase, a marker of zinc status, for which decrease was associated with improvement only with risperidone, not with placebo. CONCLUSION: The benefit-risk ratio of risperidone is better with greater symptom severity. Risperidone can be individually titrated to optimal dosage for excellent response in the majority of children. Weight gain is not necessary for risperidone benefit and may even detract from it. Socioeconomic advantage, low prolactin, and absence of co-morbid problems nonspecifically predict better outcome. Mineral interactions with risperidone deserve further study.
RCT Entities:
OBJECTIVE/ BACKGROUND: The National Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology (RUPP) Autism Network found an effect size of d = 1.2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder. This paper explores moderators and mediators of this effect. METHOD: Intention-to-treat (ITT) analyses were conducted with suspected moderators and mediators entered into the regression equations. MacArthur Foundation Network subgroup guidelines were followed in the evaluation of the results. RESULTS: Only baseline severity moderated treatment response: Higher severity showed greater improvement for risperidone but not for placebo. Weight gain mediated treatment response negatively: those who gained more weight improved less with risperidone and more with placebo. Compliance correlated with outcome for risperidone but not placebo. Higher dose correlated with worse outcome for placebo, but not risperidone. Of nonspecific predictors, parent education, family income, and low baseline prolactin positively predicted outcome; anxiety, bipolar symptoms, oppositional-defiant symptoms, stereotypy, and hyperactivity negatively predicted outcome. Risperidone moderated the effect of change in 5'-nucleotidase, a marker of zinc status, for which decrease was associated with improvement only with risperidone, not with placebo. CONCLUSION: The benefit-risk ratio of risperidone is better with greater symptom severity. Risperidone can be individually titrated to optimal dosage for excellent response in the majority of children. Weight gain is not necessary for risperidone benefit and may even detract from it. Socioeconomic advantage, low prolactin, and absence of co-morbid problems nonspecifically predict better outcome. Mineral interactions with risperidone deserve further study.
Authors: L Scahill; M A Riddle; M McSwiggin-Hardin; S I Ort; R A King; W K Goodman; D Cicchetti; J F Leckman Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-06 Impact factor: 8.829
Authors: David J Klein; Elizabeth M Cottingham; Michael Sorter; Bruce A Barton; John A Morrison Journal: Am J Psychiatry Date: 2006-12 Impact factor: 18.112
Authors: C W Bales; R A DiSilvestro; K L Currie; C S Plaisted; H Joung; A N Galanos; P H Lin Journal: J Am Coll Nutr Date: 1994-10 Impact factor: 3.169
Authors: Eric A Storch; Elysse B Arnold; Anna M Jones; Chelsea M Ale; Jeffrey J Wood; Jill Ehrenreich-May; Adam B Lewin; P Jane Mutch; Tanya K Murphy Journal: Child Psychiatry Hum Dev Date: 2012-10
Authors: Cristan Farmer; Luc Lecavalier; Sunkyung Yu; L Eugene Arnold; Christopher J McDougle; Lawrence Scahill; Benjamin Handen; Cynthia R Johnson; Kimberly A Stigler; Karen Bearss; Naomi B Swiezy; Michael G Aman Journal: J Autism Dev Disord Date: 2012-06
Authors: Bryan H King; Kimberly Dukes; Craig L Donnelly; Linmarie Sikich; James T McCracken; Lawrence Scahill; Eric Hollander; Joel D Bregman; Evdokia Anagnostou; Fay Robinson; Lisa Sullivan; Deborah Hirtz Journal: JAMA Pediatr Date: 2013-11 Impact factor: 16.193
Authors: José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui Journal: Eur Child Adolesc Psychiatry Date: 2013-03-17 Impact factor: 4.785